Curium Court Victory Clears Path for U.S. GEP-NET Therapy
BOSTON, MA, June 18, 2026 Curium™ has secured a significant legal and commercial milestone after prevailing in a patent...
targeted therapy
Advertisement
Mabwell Showcases Strong 9MW2821 Cervical Cancer Data
COPENHAGEN, Denmark, June 18, 2026 Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, has unveiled encouraging...
Oncolytics Reports Promising Pelareorep Data in RAS Cancers
SAN DIEGO, California, USA, June 1, 2026 Oncolytics Biotech has announced encouraging preclinical findings for pelareorep in combination with...
SystImmune’s BL-M14D1 Shows Strong Activity in SCLC
REDMOND, Wash., June 1, 2026 SystImmune has reported encouraging Phase 1 clinical data for its investigational DLL3-targeting antibody-drug conjugate...
Servier’s Emi-Le Shows Promise in Rare ACC Cancer Trial
BOSTON, June 1, 2026 Servier has announced encouraging new clinical findings for Emiltatug Ledadotin (Emi-Le), an investigational B7-H4-targeted antibody-drug...
Advertisements
Curium Invests €32M to Expand Prostate Cancer RLT Production
PARIS, France, June 1, 2026 Curium, a global leader in radiopharmaceuticals and nuclear medicine, has announced a strategic investment...
Revolution Medicines Daraxonrasib Doubles Survival in PDAC
REDWOOD CITY, Calif., May 31, 2026 Revolution Medicines has announced unprecedented results from its pivotal Phase 3 RASolute 302...
Servier’s VORANIGO® Delivers More Than 44 Months of Progression-Free Survival in IDH-Mutant Glioma
BOSTON, Massachusetts, May 31, 2026 Servier has announced extended follow-up results from the pivotal Phase 3 INDIGO trial, demonstrating...
Dizal Highlights Promising NSCLC Therapies at ASCO 2026
May 31, 2026 – Chicago, Illinois, USA Dizal has unveiled encouraging clinical findings for two innovative non-small cell lung...
Pfizer Reports Landmark Seven-Year LORBRENA Data in Advanced ALK-Positive Lung Cancer
NEW YORK | May 29, 2026 Pfizer announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial, demonstrating...
Advertisement
